Physician profile
William J Barlow
NPI 1700073251
$2,422.14
in general payments reported to CMS, 2019-2025
15 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $115 · 2021: $425 · 2022: $362 · 2023: $368 · 2024: $437 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,125.34 | 2019-2025 | Linzess, Mavyret, Skyrizi |
| Merck Sharp & Dohme LLC | $257.05 | 2021-2024 | Dificid, Zerbaxa, Zinplava |
| Pfizer INC. | $255.79 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.00 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $123.88 | 2021-2023 | Stelara |
| Gilead Sciences, INC. | $123.24 | 2020-2025 | |
| Boston Scientific Corporation | $83.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.38 | 2019-2025 | Entyvio, Gattex |
| Aimmune Therapeutics, INC. | $48.38 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $34.75 | 2021-2022 | |
| Celgene Corporation | $31.32 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $26.37 | 2023 | Ocaliva |
| Lilly USA, LLC | $24.08 | 2025 | Omvoh |
| Pentax of America, INC. | $19.90 | 2020 | |
| Novo Nordisk INC | $17.00 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.